{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:39:12Z","timestamp":1791920352221,"version":"4.3.4"},"reference-count":63,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100001427","name":"All India Council for Technical Education","doi-asserted-by":"publisher","award":["1-4017935721"],"award-info":[{"award-number":["1-4017935721"]}],"id":[{"id":"10.13039\/501100001427","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Schizophrenia is a chronic neuropsychiatric disorder that affects nearly 1% of the global\npopulation. There are various anti-psychotic drugs available for the treatment of schizophrenia, but\nthey have certain side effects; therefore, there is a need to explore and develop novel potential lead\ncompounds against schizophrenia. The currently available drugs e.g. typical and atypical antipsychotics\nact on different dopamine and serotonin receptors and as per literature reports, various piperidine\nand piperazine derivatives have shown promising activity against these receptors. When different heterocyclic\ngroups are attached to basic piperidine and piperazine rings, the antipsychotic activity is\ngreatly potentiated. In this direction, various antipsychotic drugs have been synthesized at the laboratory\nlevel, and few are under clinical trial studies, such as Lu AE58054, PF-04802540, ORG25935,\nDMXB-A, Bitopertin, and ABT-126. In the present review, we include the studies related to the effect\nof different substituents on piperidine\/piperazine derivatives and their anti-psychotic activity. Various\nseries of synthesized compounds by other researchers with piperidine\/piperazine nucleus have been\nreviewed and diagrammatically represented in the form of SAR (structure-activity relationships),\nwhich will help the scientists for the development of potential lead compounds.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389557520666200910092327","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T03:59:06Z","timestamp":1599796746000},"page":"362-379","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The Recent Development of Piperazine and Piperidine Derivatives as Antipsychotic Agents"],"prefix":"10.2174","volume":"21","author":[{"given":"Akash","family":"Rathore","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Dr. Harisingh Gour University (A Central University), Sagar (MP),India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Asati","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Dr. Harisingh Gour University (A Central University), Sagar (MP),India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil Kumar","family":"Kashaw","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Dr. Harisingh Gour University (A Central University), Sagar (MP),India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivangi","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Dr. Harisingh Gour University (A Central University), Sagar (MP),India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Parwani","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Dr. Harisingh Gour University (A Central University), Sagar (MP),India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushanta","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Dr. Harisingh Gour University (A Central University), Sagar (MP),India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitali","family":"Mallick","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Dr. Harisingh Gour University (A Central University), Sagar (MP),India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.psychres.2012.05.008","volume":"200","author":"Ekerholm M.","year":"2012","unstructured":"Ekerholm M.; Firus Waltersson S.; Fagerberg T.; S\u00f6derman E.; Terenius L.; Agartz I.; J\u00f6nsson E.G.; Nyman H.; Neurocognitive function in long-term treated schizophrenia: A five-year follow-up study. Psychiatry Res 2012,200(2-3),144-152","journal-title":"Psychiatry Res"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1124\/pr.114.009944","volume":"67","author":"Michino M.","year":"2015","unstructured":"Michino M.; Beuming T.; Donthamsetti P.; Newman A.H.; Javitch J.A.; Shi L.; What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands? Pharmacol Rev 2015,67(1),198-213","journal-title":"Pharmacol Rev"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev.med.52.1.503","volume":"52","author":"Kapur S.","year":"2001","unstructured":"Kapur S.; Remington G.; Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001,52(1),503-517","journal-title":"Annu Rev Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1017\/S0033291700012976","volume":"17","author":"Liddle P.F.","year":"1987","unstructured":"Liddle P.F.; Schizophrenic syndromes, cognitive performance and neurological dysfunction. Psychol Med 1987,17(1),49-57","journal-title":"Psychol Med"},{"key":"ref=5","first-page":"1","volume":"2","author":"McCutcheon R.A.","year":"2019","unstructured":"McCutcheon R.A.; Reis Marques T.; Howes O.D.; Schizophrenia-An overview. JAMA Psychiatry 2019,2,1-10","journal-title":"JAMA Psychiatry"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.bmc.2011.12.019","volume":"20","author":"Peprah K.","year":"2012","unstructured":"Peprah K.; Zhu X.Y.; Eyunni S.V.; Setola V.; Roth B.L.; Ablordeppey S.Y.; Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents. Bioorg Med Chem 2012,20(3),1291-1297","journal-title":"Bioorg Med Chem"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ejmech.2018.01.002","volume":"145","author":"Zajdel P.","year":"2018","unstructured":"Zajdel P.; Kos T.; Marciniec K.; Sata\u0142a G.; Canale V.; Kami\u0144ski K.; Ho\u0142uj M.; Lenda T.; Koralewski R.; Bednarski M.; Nowi\u0144ski L.; W\u00f3jcikowski J.; Daniel W.A.; Nikiforuk A.; Nalepa I.; Chmielarz P.; Ku\u015bmierczyk J.; Bojarski A.J.; Popik P.; Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects. Eur J Med Chem 2018,145,790-804","journal-title":"Eur J Med Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.neubiorev.2010.02.001","volume":"35","author":"Ikemoto S.","year":"2010","unstructured":"Ikemoto S.; Brain reward circuitry beyond the mesolimbic dopamine system: A neurobiological theory. Neurosci Biobehav Rev 2010,35(2),129-150","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/schbul\/sbn135","volume":"35","author":"Buckley P.F.","year":"2009","unstructured":"Buckley P.F.; Miller B.J.; Lehrer D.S.; Castle D.J.; Psychiatric comorbidities and schizophrenia. Schizophr Bull 2009,35(2),383-402","journal-title":"Schizophr Bull"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"7483","DOI":"10.1021\/acs.jmedchem.7b00839","volume":"60","author":"Bucki A.","year":"2017","unstructured":"Bucki A.; Marcinkowska M.; \u015aniecikowska J.; Wi\u0119ckowski K.; Paw\u0142owski M.; G\u0142uch-Lutwin M.; Grybo\u015b A.; Siwek A.; Pytka K.; Jastrz\u0119bska-Wi\u0119sek M.; Partyka A.; Weso\u0142owska A.; Mierzejewski P.; Ko\u0142aczkowski M.; Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based multifunctional ligands with antipsychotic-Like, mood-modulating, and procognitive activity. J Med Chem 2017,60(17),7483-7501","journal-title":"J Med Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"Leucht S.","year":"2013","unstructured":"Leucht S.; Cipriani A.; Spineli L.; Mavridis D.; \u00d6rey D.; Richter F.; Samara M.; Barbui C.; Engel R.R.; Geddes J.R.; Kissling W.; Stapf M.P.; L\u00e4ssig B.; Salanti G.; Davis J.M.; Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet 2013,382(9896),951-962","journal-title":"Lancet"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/S1092852918001013","volume":"23","author":"Stahl S.M.","year":"2018","unstructured":"Stahl S.M.; Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: Dopamine, serotonin, and glutamate. CNS Spectr 2018,23(3),187-191","journal-title":"CNS Spectr"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"5299","DOI":"10.1016\/j.bmcl.2015.09.045","volume":"25","author":"Huang L.","year":"2015","unstructured":"Huang L.; Zhang W.; Zhang X.; Yin L.; Chen B.; Song J.; Synthesis and pharmacological evaluation of piperidine (piperazine)-substituted benzoxazole derivatives as multi-target antipsychotics. Bioorg Med Chem Lett 2015,25(22),5299-5305","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/archpsyc.64.10.1115","volume":"64","author":"Goldberg T.E.","year":"2007","unstructured":"Goldberg T.E.; Goldman R.S.; Burdick K.E.; Malhotra A.K.; Lencz T.; Patel R.C.; Woerner M.G.; Schooler N.R.; Kane J.M.; Robinson D.G.; Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: Is it a practice effect? Arch Gen Psychiatry 2007,64(10),1115-1122","journal-title":"Arch Gen Psychiatry"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejmech.2017.12.099","volume":"145","author":"Xu M.","year":"2018","unstructured":"Xu M.; Wang Y.; Yang F.; Wu C.; Wang Z.; Ye B.; Jiang X.; Zhao Q.; Li J.; Liu Y.; Zhang J.; Tian G.; He Y.; Shen J.; Jiang H.; Synthesis and biological evaluation of a series of multi-target N-substituted cyclic imide derivatives with potential antipsychotic effect. Eur J Med Chem 2018,145,74-85","journal-title":"Eur J Med Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1017\/S0033291709005455","volume":"39","author":"Leucht S.","year":"2009","unstructured":"Leucht S.; Kissling W.; Davis J.M.; Second-generation antipsychotics for schizophrenia: Can we resolve the conflict? Psychol Med 2009,39(10),1591-1602","journal-title":"Psychol Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/1570163815666181008151718","volume":"17","author":"Kumar A.","year":"2020","unstructured":"Kumar A.; Singh H.; Mishra A.; Mishra A.K.; aripiprazole: An fda approved bioactive compound to treat schizophrenia- a mini review. Curr Drug Discov Technol 2020,17(1),23-29","journal-title":"Curr Drug Discov Technol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/JCP.0000000000000063","volume":"34","author":"Nagoshi Y.","year":"2014","unstructured":"Nagoshi Y.; Tominaga T.; Fukui K.; Effect of aripiprazole augmentation for treatment-resistant somatoform disorder: A case series. J Clin Psychopharmacol 2014,34(3),397-398","journal-title":"J Clin Psychopharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1089\/cap.2018.0068","volume":"28","author":"Pan P.Y.","year":"2018","unstructured":"Pan P.Y.; Fu A.T.; Yeh C.B.; Aripiprazole\/methylphenidate combination in children and adolescents with disruptive mood dysregulation disorder and attention-deficit\/hyperactivity disorder: An open-label study. J Child Adolesc Psychopharmacol 2018,28(10),682-689","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref=20","author":"Modugula H.","year":"2020","unstructured":"Modugula H.; Kumar A.;  Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression, CNS  2020","journal-title":"Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression, CNS"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1021\/jm800689g","volume":"52","author":"Butini S.","year":"2009","unstructured":"Butini S.; Gemma S.; Campiani G.; Franceschini S.; Trotta F.; Borriello M.; Ceres N.; Ros S.; Coccone S.S.; Bernetti M.; De Angelis M.; Brindisi M.; Nacci V.; Fiorini I.; Novellino E.; Cagnotto A.; Mennini T.; Sandager-Nielsen K.; Andreasen J.T.; Scheel-Kruger J.; Mikkelsen J.D.; Fattorusso C.; Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. J Med Chem 2009,52(1),151-169","journal-title":"J Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41594-018-0180-z","volume":"26","author":"Kimura K.T.","year":"2019","unstructured":"Kimura K.T.; Asada H.; Inoue A.; Kadji F.M.N.; Im, D.; Mori, C.; Arakawa, T.; Hirata, K.; Nomura, Y.; Nomura, N.; Aoki, J.; Iwata, S.; Shimamura, T. Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine. Nat Struct Mol Biol 2019,26(2),121-128","journal-title":"Nat Struct Mol Biol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nature25758","volume":"555","author":"Wang S.","year":"2018","unstructured":"Wang S.; Che T.; Levit A.; Shoichet B.K.; Wacker D.; Roth B.L.; Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature 2018,555(7695),269-273","journal-title":"Nature"},{"key":"ref=24","first-page":"22","volume":"61","author":"Cao X.","year":"2018","unstructured":"Cao X.; Zhang Y.; Chen Y.; Qiu Y.; Yu M.; Xu X.; Liu X.; Liu B.F.; Zhang L.; Zhang G.; Synthesis and biological evaluation of fused tricyclic heterocycle piperazine (Piperidine) derivatives as potential multireceptor atypical antipsychotics. J Med Chem 2018,61,22","journal-title":"J Med Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"9578","DOI":"10.1021\/jm501119j","volume":"57","author":"Brindisi M.","year":"2014","unstructured":"Brindisi M.; Butini S.; Franceschini S.; Brogi S.; Trotta F.; Ros S.; Cagnotto A.; Salmona M.; Casagni A.; Andreassi M.; Saponara S.; Gorelli B.; Weikop P.; Mikkelsen J.D.; Scheel-Kruger J.; Sandager-Nielsen K.; Novellino E.; Campiani G.; Gemma S.; Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: Synthesis, biological characterization, and behavioral studies. J Med Chem 2014,57(22),9578-9597","journal-title":"J Med Chem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1021\/jm400408r","volume":"56","author":"Chen Y.","year":"2013","unstructured":"Chen Y.; Wang S.; Xu X.; Liu X.; Yu M.; Zhao S.; Liu S.; Qiu Y.; Zhang T.; Liu B.F.; Zhang G.; Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics. J Med Chem 2013,56(11),4671-4690","journal-title":"J Med Chem"},{"key":"ref=27","first-page":"4","volume":"7","author":"Chen Y.","year":"2012","unstructured":"Chen Y.; Xu X.; Liu X.; Yu M.; Liu B.F.; Zhang, G Synthesis and evaluation of a series of 2-substituted-5-thiopropylpiperazine (piperidine)-1, 3, 4-oxadiazoles derivatives as atypical antipsychotics. PLoS One 2012,7,4","journal-title":"PLoS One"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1016\/j.bmc.2017.07.040","volume":"25","author":"Xiamuxi H.","year":"2017","unstructured":"Xiamuxi H.; Wang Z.; Li J.; Wang Y.; Wu C.; Yang F.; Jiang X.; Liu Y.; Zhao Q.; Chen W.; Zhang J.; Xie Y.; Hu T.; Xu M.; Guo S.; Akber Aisa H.; He Y.; Shen J.; Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics. Bioorg Med Chem 2017,25(17),4904-4916","journal-title":"Bioorg Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.bmcl.2018.01.038","volume":"28","author":"Xu M.","year":"2018","unstructured":"Xu M.; Wang Y.; Yang F.; Wu C.; Wang Z.; Ye B.; Jiang X.; Zhao Q.; Li J.; Liu Y.; Zhang J.; Tian G.; He Y.; Shen J.; Jiang H.; Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs. Bioorg Med Chem Lett 2018,28(4),606-611","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1039\/C4MD00578C","volume":"6","author":"Chen Y.","year":"2015","unstructured":"Chen Y.; Lan Y.; Cao X.; Xu X.; Zhang J.; Yu M.; Liu X.; Liu B.F.; Zhang G.; Synthesis and evaluation of amide, sulfonamide, and urea\u2013benzisoxazole derivatives as potential atypical antipsychotics. MedChemComm 2015,6(5),831-838","journal-title":"MedChemComm"},{"key":"ref=31","first-page":"161","volume":"291","author":"Cartmell J.","year":"1999","unstructured":"Cartmell J.; Monn J.A.; Schoepp D.D.; The metabotropic glutamate 2\/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 1999,291(1),161-170","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=32","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/736439","volume":"2013","author":"Menezes M.M.","year":"2013","unstructured":"Menezes M.M.; Santini M.A.; Benvenga M.J.; Marek G.J.; Merchant K.M.; Mikkelsen J.D.; Svensson K.A.; The mGlu2\/3 receptor agonists LY354740 and LY379268 differentially regulate restraint-stress-induced expression of c-Fos in rat cerebral cortex. Neurosci J 2013,2013","journal-title":"Neurosci J"},{"key":"ref=33","author":"Siever L.J.","year":"2013","unstructured":"Siever L.J.; Zaluda L.C.; McClure M.M.; . Clinical testing of a D1\n agonist for cognitive enhancement in the schizophrenia spectrum\n 14th International Congress on Schizophrenia Research 2013"},{"key":"ref=34","unstructured":"Pharmacologic and clinical testing of a D1 agonist for cognitive\n183 enhancement in neuropsychiatric disorders"},{"key":"ref=35","unstructured":"Brexpiprazole in patients with acute schizophrenia"},{"key":"ref=36","first-page":"11","volume":"20","author":"Fleischhacker W.W.","year":"2017","unstructured":"Fleischhacker W.W.; Hobart M.; Ouyang J.; Forbes A.; Pfister S.; McQuade R.D.; Carson W.H.; Sanchez R.; Nyilas M.; Weiller E.; Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia a randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2017,20(1),11-21","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/B978-0-12-396492-2.00030-8","volume":"47","author":"Notte G.T.","year":"2012","unstructured":"Notte G.T.; New chemical entities entering phase III trials in 2011. Annu Rep Med Chem 2012,47,477-498","journal-title":"Annu Rep Med Chem"},{"key":"ref=38","unstructured":"A 6-month, randomized, double-blind, parallel-group, risperidonecontrolled,\nfixed-dose study evaluating the safety and efficacy of\nzicronapinein patients with schizophrenia EU clinical trials register,"},{"key":"ref=39","unstructured":"Efficiency study to investigate blonanserin in treatment of schizophrenia\n when compared with risperidone"},{"key":"ref=40","author":"Turk Tarek.","year":"2017","unstructured":"Turk Tarek.; Alkhatib Mahmoud.; Morfin, Natalia Hernandez Blonanserin versus risperidone for schizophrenia The.. Cochrane database  of systematic reviews 2017","journal-title":"Cochrane database  of systematic reviews"},{"key":"ref=41","unstructured":"A multi-center, inpatient and ambulatory, Phase II, double-blind,\n randomized, placebo-controlled proof of concept study of CYR-\n 101 in patients with DSM-IV schizophrenia EU clinical trials register,"},{"key":"ref=42","unstructured":"Study of CYR-101 in patients with schizophrenia"},{"key":"ref=43","author":"Saoud J.","year":"2019","unstructured":"Saoud J.; Luthringer R.; Werner S.; Noel N.; Georgi E.;  MINERVA\n NEUROSCIENCES Inc, assignee Gastro-resistant controlled\n release oral dosage forms United States patent application US\n  2019"},{"key":"ref=44","first-page":"2","volume":"2","author":"Hesselink J.M.","year":"2016","unstructured":"Hesselink J.M.; Keppel, Idalopirdine (LY483518, SGS518, Lu AE 58054) in Alzheimer\u2019s disease: never change a winning team and do not build exclusively on surrogates. Lessons Learned from Drug Development Trials. J Pharmacol Clin Res 2016,2,2","journal-title":"J Pharmacol Clin Res"},{"key":"ref=45","author":"Ramirez MJ","year":"2014","unstructured":"Ramirez MJ; Lai MK; Tordera RM; Francis PT;  Serotonergic therapies for cognitive symptoms in Alzheimer\u2019s disease rationale and current status 2014","journal-title":"Serotonergic therapies for cognitive symptoms in Alzheimer\u2019s disease rationale and current status"},{"key":"ref=46","author":"Meltzer Herbert Y.","year":"2014","unstructured":"Meltzer Herbert Y.;  Method for treating schizophrenia and related\n diseases U.S. Patent No 2014"},{"key":"ref=47","unstructured":"Multipledose safety study of PF-04802540 in subjects with schizophrenia"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.2174\/0929867326666190710172002","volume":"26","author":"Jankowska A.","year":"2019","unstructured":"Jankowska A.; Sata\u0142a G.; Partyka A.; Weso\u0142owska A.; Bojarski A.J.; Paw\u0142owski M.; Ch\u0142o\u0144-Rzepa G.; Discovery and development of non-dopaminergic agents for the treatment of schizophrenia an overview of the preclinical and early clinical studies. Curr Med Chem 2019,26(25),4885-4913","journal-title":"Curr Med Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1111\/acer.12501","volume":"38","author":"de Bejczy A.","year":"2014","unstructured":"de Bejczy A.; Nations K.R.; Szegedi A.; Schoemaker J.; Ruwe F.; S\u00f6derpalm B.; Efficacy and safety of the glycine transporter-1 inhibitor org 25935 for the prevention of relapse in alcohol-dependent patients: A randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2014,38(9),2427-2435","journal-title":"Alcohol Clin Exp Res"},{"key":"ref=50","unstructured":"Adjuvant treatment with a glycine uptake inhibitor in subjects with\n chronic schizophrenia"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00213-013-3260-0","volume":"231","author":"Eddins D.","year":"2014","unstructured":"Eddins D.; Hamill T.G.; Puri V.; Cannon C.E.; Vivian J.A.; Sanabria-Boh\u00f3rquez S.M.; Cook J.J.; Morrow J.A.; Thomson F.; Uslaner J.M.; The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey. Psychopharmacology (Berl) 2014,231(3),511-519","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=52","first-page":"5","volume":"55","year":"2004","unstructured":"Tsai, Guochuan Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 2004,55,5","journal-title":"Biological Psychiatry"},{"key":"ref=53","unstructured":"Effect of sarcosine on symptomatology, quality of life, oxidative\n stress and glutamatergic parametersin schizophrenia(PULSAR)"},{"key":"ref=54","unstructured":"Sarcosine(N-methylglycine)monotherapy for schizophrenia"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2009.196","volume":"35","author":"Tregellas J.R.","year":"2010","unstructured":"Tregellas J.R.; Olincy A.; Johnson L.; Tanabe J.; Shatti S.; Martin L.; Singel D.; Du Y.; Soti F.; Kem W.; Freedman R.; Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia. Neuropsychopharmacology 2010,35,4","journal-title":"Neuropsychopharmacology"},{"key":"ref=56","unstructured":"Trial of DMXB-A in schizophrenia"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.biopsych.2016.11.014","volume":"82","author":"Bugarski-Kirola D.","year":"2017","unstructured":"Bugarski-Kirola D.; Blaettler T.; Arango C.; Fleischhacker W.W.; Garibaldi G.; Wang A.; Dixon M.; Bressan R.A.; Nasrallah H.; Lawrie S.; Napieralski J.; Ochi-Lohmann T.; Reid C.; Marder S.R.; Bitopertin in negative symptoms of schizophrenia results from the phase III Flash Lyte and Day Lyte studies. Biol Psychiatry 2017,82(1),8-16","journal-title":"Biol Psychiatry"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1517\/13543784.2014.987339","volume":"24","author":"Garay R.P.","year":"2015","unstructured":"Garay R.P.; Samalin L.; Hameg A.; Llorca P.M.; Investigational drugs for anxiety in patients with schizophrenia. Expert Opin Investig Drugs 2015,24(4),507-517","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=59","unstructured":"A study of RO4917838 (Bitopertin) in patients with sub-optimally controlled symptoms ofschizophrenia"},{"key":"ref=60","first-page":"3","volume":"79","author":"Haig G.M.","year":"2018","unstructured":"Haig G.M.; Wang D.; Zhao J.; Othman A.A.; Bain E.E.; Efficacy and Safety of the \u03b17-Nicotinic acetylcholine receptor agonist ABT-126 in the treatment of cognitive impairment associated with schizophrenia results from a phase 2b randomized controlled Study in Smokers. J Clin Psychiat 2018,79,3","journal-title":"J Clin Psychiat"},{"key":"ref=61","unstructured":"A randomized, double-blind, placebo controlled, dose-ranging,\n parallel-group study of the safety and efficacy of ABT-126 in the\n treatment of cognitive deficits in schizophrenia (CDS) EU clinical"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/npp.2016.101","volume":"41","author":"Haig G.","year":"2016","unstructured":"Haig G.; Wang D.; Othman A.; Zhao, J the \u03b17 nicotinic agonist ABT-126 in the treatment of cognitive impairment associated with schizophrenia in nonsmokers results from a randomized controlled phase 2b study. Neuropsychopharmacology 2016,41,12","journal-title":"Neuropsychopharmacology"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2215-0366(17)30046-9","volume":"4","author":"Yatham L.N.","year":"2017","unstructured":"Yatham L.N.; Mackala S.; Basivireddy J.; Ahn S.; Walji N.; Hu C.; Lam R.W.; Torres I.J.; Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: A randomised, open-label, pilot study. Lancet Psychiat 2017,4(3),208-217","journal-title":"Lancet Psychiat"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557520666200910092327","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185797\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557520666200910092327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T07:57:02Z","timestamp":1660463822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185797\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557520666200910092327","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}